The concept that susceptibility to multiple sclerosis (MS) is, in part, conferred by genetics and, in part, by the environment could not be more relevant today. Indeed, more than 200 genomic loci have been associated with MS risk and yet, only ~30% of that risk can be explained by these DNA variants. Environmental factors must, therefore, explain a significant proportion of the remaining risk. Paradoxically, it has been more straightforward to study the genome than the environment. The genome is stable over a lifespan, is the same in every cell, and can be analyzed reproducibly and quickly at an affordable cost. In contrast, studies that attempt at elucidating the influence of environmental mediators of diseases can be complicated to design and to interpret. They often rely on epidemiological data including patients' recall of prior exposures (e.g. sun and viral infections) and typically require extremely large sample sizes to account for the many possible confounding factors.
In considering the identification of additional environmental mediators of MS, the gut is a natural place to look given its critical role in regulating immune responses, and thus, characterization of local bacterial communities (microbiota) and their genes (microbiome) has prompted much attention by MS researchers worldwide. Recent advances in DNA sequencing have enabled the systematic and quantitative study of entire populations of microorganisms (i.e. microbiomes) that inhabit our bodies in a symbiotic relationship. Recent work by the Human Microbiome Project 1 has uncovered the richness and diversity of these communities and highlighted their close dependence on diet and other external stimuli. In this sense, the gut microbiome can be considered a window into the environment, the non-genetic component of MS risk that has eluded scientists for decades.
In this forum, three speakers described the state of the field and presented their own contributions. Dr Irah King (McGill University, Montreal) provided an overview of the renewed interest in microbial biology and its implication for human health. He reviewed the influence of environmental factors on shaping microbial composition and described the technical aspects of how the microbiome is analyzed and how studies are designed in both animals and humans. He further highlighted the importance of the gut microbiota in regulating metabolism and host defense, including important influences on immune system development. On this topic, Dr King highlighted the hypothetical existence of a "gut-brain axis," in which gut bacteria (either directly or indirectly) modulate behavior, development, and even induce pathogenesis. He provided specific examples by reviewing publications related to MS including earlier studies in experimental autoimmune encephalomyelitis (EAE) and more recent studies in MS patients. For example, he discussed the attenuation of EAE in germ-free as compared to specific pathogen-free mice, 2,3 in mice treated with oral antibiotics as compared to controls or those treated with intraperitoneal antibiotics 4 and in those treated with bacterially-derived metabolites. 5, 6 Dr King also discussed the possibility of microbiota-derived metabolites acting through the aryl hydrocarbon receptor 7 and that MS patients may have "dysbiosis." 8 Finally, he described potential effects of microbiota on permeability of the blood-brain barrier,
The microbiome and MS: The influence of the microbiota on MS risk and progression-Session chair summary neurogenesis/neuronal survival, myelination, and microglia. On this regard, he discussed reported local effects of changes in microbial composition of the brain in MS patients. Dr King concluded with suggested future research directions including functional studies in animal models and MS patients to elucidate strategies for microbial-based therapies.
Dr Howard Weiner (Partners MS Center, Boston) presented his research on Probiotics as Therapy for MS. He began by discussing the rationale for studying probiotics in MS, namely, that they are administered orally, are non-toxic, and are able to influence microbial composition and induce regulatory T cells. He continued on by discussing available evidence for the probiotic VSL#3 (Bifidobacterium/Lactobacillus/Streptococcus) in animal models of diabetes, colitis, and allergy as well as human studies in inflammatory bowel disease and other conditions. He then presented their group's pilot study of administration of VSL#3 twice daily for 2 months in 9 MS patients and 13 healthy controls, with collection of blood and stool samples at baseline, study conclusion, and 3 months later. The investigators were able to demonstrate an increase in the relative abundance of species present in VSL#3 in both MS patients and healthy controls, with decrease to levels similar to baseline by 3 months after therapy discontinuation. Interestingly, they were also able to detect differences in peripheral immune function. Specifically, after administration of VSL #3, they noted a decrease in proinflammatory monocytes and in markers of monocyte and dendritic cell activation. After discontinuation of VSL#3 they noted an increase in pro-inflammatory monocytes, a decrease in IL-10 regulatory T cells, and a decrease in latency-associated peptide expression on peripheral blood mononuclear cells.
Dr Helen Tremlett (University of British Columbia, Vancouver) presented her work entitled "Gut Microbiome and Pediatric Multiple Sclerosis." She began by discussing the rationale for studying the microbiome in MS and particularly the opportunities afforded by studying pediatric MS as there is a clear focused "at risk" period close to disease onset and the likelihood of obtaining accurate exposure information is greater as compared to adults. The first study she presented aimed at evaluating whether gut microbial composition differs between children with MS and healthy controls. 9 About 18 MS cases (mean age 12, disease duration 10.6 months, and 9/18 on diseasemodifying therapy) and 17 controls were recruited at the pediatric MS clinic at UCSF. Not surprisingly, and in line with previous studies, both alpha diversity and beta diversity were similar among cases and controls. However, taxa-level differences were observed that suggested a more "pro-inflammatory milieu" among MS patients. She noted that a potential limitation of this study is the small sample size and the presence of confounders, particularly, disease-modifying therapy. In this study, half of the patients were receiving immunomodulatory drugs, and this may have contributed to the heterogeneity and perhaps the signal detected in their statistical analysis. Ongoing work elsewhere is directed toward understanding the effect of therapeutic drugs on the composition of the gut microbiota in MS given important effects of therapeutics observed in other disease states such as diabetes. 10, 11 Similarly, studies on how host microbiota influences the efficacy of specific therapies are also underway.
In a second study, using the same cohort, Dr Tremlett et al. 12 investigated whether microbial composition was related to risk for MS relapse. They noted that of the eight phyla with sufficient data to be examined (detected in >20% of cases), three patterns were associated with the suggestion of shorter time to relapse: absence of Fusobacteria, higher abundance of Firmicutes, and presence of Archaea Euryarchaeota, though only the absence of Fusobacteria remained significant after adjustment for age and disease-modifying therapy and statistical corrections (Hazard Ratio 3.2). The results of these studies are intriguing and warrant further research, particularly confirmation in larger data sets.
In summary, this session reviewed current work attempting to elucidating the role of the gut microbiome in MS and EAE. The session was well attended, underscoring the general interest this topic stimulates among researchers. This is a very active research field and more contributions are expected in months and years to come.
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